Baxter Divests Serum Business In Turkey Business Rejig
Executive Summary
In alignment with the global separation of its Baxalta biopharmaceutical business, Baxter will complete a major reorganization in Turkey by the end of the year that includes the sale of its local serum products portfolio and production equipment to a fast-growing local firm.
You may also be interested in...
Turkey Jostles For Slice Of Biologics Manufacturing Pie
Many local pharma companies in Turkey have been launching capital investments in new production facilities for biologics and biosimilars in the hope of attracting new foreign partners and have already met with some success, but a number of obstacles remain.
Medtech Procurement A Victim Of Turkey’s Ongoing Economic Troubles
The devaluation of the Turkish Lira since May is making imports of medical devices more expensive and putting hospital procurement under renewed pressure. The local medtech industry associations TUMDEF and ARTED describe the problems ̶ and the solutions ̶ to Medtech Insight.
A Bright Moment At Last In Turkish Medtech Debt Payments Saga
Turkish medtechs’ demands for payment of their outstanding hospital debts went unheeded in 2021, but the government has finally started a payment process. It is not evenly applied, and has started in a small way, but the industry feels encouraged on more than one count.